Abstract
Undoubtedly, the development of COVID-19 vaccines displays a critical step towards ending this devastating pandemic, considering their protective benefits in the general population. Yet, data regarding their efficacy and safety in cancer patients are limited. Herein we provide the initial analysis of immune responses after the first dose of vaccination in 21 breast cancer patients receiving cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors. The levels of neutralizing antibodies post vaccination were similar to the matched healthy controls, whereas no safety issues have been raised. Further exploration is needed to reduce the uncertainty of SARS-CoV-2 immunity among cancer patients under treatment.
Keywords: Breast cancer; CDK4/6 inhibitors; COVID-19; Vaccination.
【저자키워드】 COVID-19, Breast cancer, vaccination, CDK4/6 inhibitors, 【초록키워드】 Treatment, neutralizing antibody, COVID-19 vaccine, immune response, vaccination, pandemic, inhibitors, SARS-CoV-2 immunity, Breast, Efficacy and safety, General population, Critical, Protective, Analysis, cancer patient, first dose, healthy controls, post vaccination, benefit, breast cancer patient, initial, raised, receiving, reduce, 【제목키워드】 inhibitor, SARS-CoV-2 neutralizing antibody, dose, first vaccination, breast cancer patient, receiving,